Companies › Healthcare

Moderna MRNA

HealthcareMarket cap $45B7 connections

Moderna's mRNA technology produced the world's second most-used COVID vaccine and is now being applied to influenza, RSV, cancer vaccines, and rare diseases. Its personalized cancer vaccine (mRNA-4157 with Merck) tailors tumor-fighting instructions to each patient's unique mutations. mRNA drug manufacturing is Moderna's platform bet - the same factory that made COVID vaccines can make any mRNA therapy.

Explore Moderna on the interactive map Relationship timeline Find a path to another company

Suppliers 4

Companies that sell to Moderna

  • Thermo FisherHealthcare · $220BmRNA manufacturing equipment
  • DanaherHealthcare · $180BManufacturing tools for vaccines
  • West PharmaceuticalHealthcare · $15BWest vial closures for Moderna mRNA vaccines
  • CatalentHealthcare · $12BDrug manufacturing

Partners 1

Strategic partnerships, joint products and alliances

  • PfizerHealthcare · $160BCompeting mRNA vaccine platforms

Competitors 3

Companies it competes with

Key relationships in depth

Moderna & Pfizer

Moderna and Pfizer were the two pioneer companies that brought mRNA vaccines to market during the COVID-19 pandemic, splitting the US mRNA vaccine market between Moderna's mRNA-1273 (Spikevax) and Pfizer-BioNTech's BNT162b2 (Comirnaty). The two companies now compete across respiratory vaccines (COVID, flu, RSV) and cancer vaccines using the same mRNA technology platform.

Why it matters: Pfizer earned over $100B from COVID vaccines and treatments (2021-2023), funding a massive pipeline expansion. Moderna, valued at $200B+ at peak, is now competing to extend mRNA beyond COVID into influenza, RSV, personalized cancer vaccines, and rare disease. The mRNA platform race will determine which company becomes the dominant vaccine and biologics franchise of the next decade.

Other Healthcare companies

Embed this on your site

Show Moderna's network in an article or report - it updates as our data does.

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.